Want to see PMN full AI Analyst Report?
PMN Stock Chart & Stats
$8.12
-$0.04(-3.74%)
At close: 4:00 PM EST
$8.12
-$0.04(-3.74%)
Day’s Range― - ―
52-Week Range$6.27 - $39.75
Previous CloseN/A
Volume32.49K
Average Volume (3M)53.34K
Market Cap
$136.22M
Enterprise Value-$50.24M
Total Cash (Recent Filing)$63.85M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.20
Next Earnings
Aug 17, 2026EPS Estimate
-1.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-23.59
Shares Outstanding8,967,693
10 Day Avg. Volume95,746
30 Day Avg. Volume53,344
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-9.53K
Price to Sales (P/S)0.00
P/FCF Ratio-426.74
Enterprise Value/Market Cap-0.37
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.37
Enterprise Value/Ebitda1.22
Forecast
1Y Price Target
$31.13Price Target Upside283.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-5.43
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA debt-free balance sheet with meaningful equity reduces financing risk and preserves strategic optionality for a clinical-stage biopharma. This structural strength lowers default risk, supports continued R&D spending, and makes the company a more viable partner or licensor over the next several months.
Targeted Antibody PlatformA platform that selectively targets pathogenic protein conformations offers a durable competitive advantage: potential for improved efficacy/safety profiles, differentiated clinical endpoints, and stronger licensing/partnership appeal. That technology focus underpins long-term strategic value independent of short-term market moves.
Governance And Talent FlexibilityExpanding the incentive plan reserve strengthens the company's ability to attract and retain experienced R&D and executive talent, which is critical for advancing clinical programs. This governance action supports long-term execution capacity and alignment of management with shareholders over upcoming development milestones.
Bears Say
Pre-revenue And Large LossesBeing pre-revenue with sizable recurring losses means the company must rely on external financing or partnerships to fund operations. This persistent deficit increases dilution risk and constrains strategic flexibility, making sustained execution on clinical programs contingent on successful capital raises or milestone deals.
Persistent Negative Cash FlowConsistent negative operating and free cash flow is a structural headwind for a development-stage biotech. Ongoing cash burn shortens runway absent financing or non-dilutive deals, limits ability to expand trials or commercial planning, and elevates execution and timing risk for any program advancement.
Equity Stability ConcernsHistorical swings to negative equity point to volatility in the capital structure and prior financing pressures. This inconsistency can deter some institutional counterparties, complicate future financing terms, and raise governance and solvency questions that persist until the company demonstrates sustained funding or commercial progress.
ProMIS Neurosciences News
PMN FAQ
What was ProMIS Neurosciences Inc.’s price range in the past 12 months?
ProMIS Neurosciences Inc. lowest stock price was $6.27 and its highest was $39.75 in the past 12 months.
What is ProMIS Neurosciences Inc.’s market cap?
ProMIS Neurosciences Inc.’s market cap is $136.22M.
When is ProMIS Neurosciences Inc.’s upcoming earnings report date?
ProMIS Neurosciences Inc.’s upcoming earnings report date is Aug 17, 2026 which is in 27 days.
How were ProMIS Neurosciences Inc.’s earnings last quarter?
ProMIS Neurosciences Inc. released its earnings results on May 12, 2026. The company reported -$1.26 earnings per share for the quarter, missing the consensus estimate of -$1.06 by -$0.2.
Is ProMIS Neurosciences Inc. overvalued?
According to Wall Street analysts ProMIS Neurosciences Inc.’s price is currently Undervalued.
Does ProMIS Neurosciences Inc. pay dividends?
ProMIS Neurosciences Inc. does not currently pay dividends.
What is ProMIS Neurosciences Inc.’s EPS estimate?
ProMIS Neurosciences Inc.’s EPS estimate is -1.41.
How many shares outstanding does ProMIS Neurosciences Inc. have?
ProMIS Neurosciences Inc. has 8,967,693 shares outstanding.
What happened to ProMIS Neurosciences Inc.’s price movement after its last earnings report?
ProMIS Neurosciences Inc. reported an EPS of -$1.26 in its last earnings report, missing expectations of -$1.06. Following the earnings report the stock price went down -1.779%.
Which hedge fund is a major shareholder of ProMIS Neurosciences Inc.?
Currently, no hedge funds are holding shares in PMN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ProMIS Neurosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.13 (283.31% Upside)
$31.13 (283.31% Upside)
Blogger Sentiment
Bullish
PMN Sentiment 70%
Sector Average 66%
Sector Average 66%
Insider Transactions
Bought Shares
Worth $45.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 8.0%
Last 30 Days ▼ 8.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
29.25%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
393.98%
Trailing 12-Months
Company Description
ProMIS Neurosciences Inc.
ProMIS Neurosciences, Inc. is a Canadian biotechnology firm dedicated to creating targeted therapeutic solutions for debilitating neurodegenerative conditions such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company leverages a unique computational discovery platform, utilizing its ProMIS and Collective Coordinates algorithms, to identify novel, disease-specific targets – known as epitopes – located on the surface of misfolded proteins. Its pipeline features several promising drug candidates, including PMN310, a monoclonal antibody designed to address toxic oligomers implicated in Alzheimer's disease. Another candidate, PMN267, targets superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS, and alpha-synuclein associated with Parkinson's disease and Lewy body dementia. Finally, PMN442 is a monoclonal antibody aimed at toxic alpha-synuclein oligomers and seeding fibrils relevant to multiple system atrophy. Established in 2004, the company changed its name from Amorfix Life Sciences Ltd. to ProMIS Neurosciences, Inc. in July 2015. Its corporate headquarters are situated in Toronto, Canada.
PMN Stock 12 Month Forecast
Average Price Target
$31.13
▲(283.31% Upside)